In Western countries, more women than men die every year of cardiovascular disease (CVD) and women spend more life years with cardiovascular disease than men. Fortunately, premature cardiovascular disease in women is preventable. Evidence-based guidelines for the prevention of cardiovascular disease in women recommend an initial risk assessment. However, recommended risk-assessment tools such as the Systematic Coronary Risk Evaluation (SCORE) system may not be sufficient to detect risk in women with obesity. A further barrier to prevention in women is the fact that physicians may underestimate the effects of risk factors that are particularly dangerous or prevalent in women. These include type 2 diabetes, hypertension, smoking, abdominal obesity, poor exercise capacity and the metabolic syndrome. Several of these factors, as well as some novel biomarkers, may increase the risk of cardiovascular disease relatively more in women than in men. To assess risk in obese women, a multifactorial assessment that encompasses assessment of body-fat distribution should be undertaken. Weight loss and lifestyle changes that have been shown to improve risk-factor profiles are crucial interventions and should be considered, even if standard risk calculators do not indicate an elevated cardiovascular risk.
narrows at older ages. An increase in risk-factor levels is associated with the age-related increase in cardiovascular disease in both sexes, but this increase is larger in women. 4 Differences in serum total cholesterol level, blood pressure, body mass index (BMI) and diabetes prevalence have been shown to explain about 50-60% of the age-related increase in coronary heart disease risk in women, compared with only about one-third of the increase in men. 4 Age-adjusted mortality from cardiovascular disease has steadily declined in the last 40 years in the population of Western countries as a result of reductions in major risk factors and improved treatment with evidence-based medical therapies. However, recent registry data from Sweden ( Figure 1 ) indicate that while there has been a steady decrease in myocardial infarction and death from ischaemic heart disease in men and in women over the age of 65 years, similar decreases were not seen in younger women. 5 One hypothesis that has been suggested regarding the lack of decrease in younger women is the effect of increasing obesity in younger women. 5 Recent data from the Renfrew-Paisley study, which recruited 15 406 individuals in Scotland between 1972 and 1976, serve to emphasise the importance of obesity as a cardiovascular disease risk factor in women. 6 In this analysis, mortality and other outcomes after 20 years were calculated according to baseline BMI. While being overweight did not increase the relative risks (RRs) for all-cause mortality, cardiovascular mortality or coronary disease, all of these were very clearly increased in obese individuals ( Figure 2 ). In terms of absolute rates of cardiovascular disease, the Renfrew-Paisley study showed that after adjusting for age, forced expiratory volume in 1 s, smoking and social class, compared with women of normal weight (BMI 18.5-24.9 kg/m 2 ) for every 100 obese women followed for 20 years, there were seven additional cases of fatal cardiovascular disease and 21 additional non-fatal cardiovascular hospitalisations attributable to obesity. The equivalent numbers among men were similar: nine additional cases of fatal cardiovascular disease and 36 additional cardiovascular hospitalisations attributable to obesity. This study, therefore, also emphasises the magnitude of the health threat posed by obesity.
In addition to reducing life expectancy, obesity before middle age is associated with an increase in the number of years lived with cardiovascular disease. This was shown in a modelling study based on a subset of the Framingham Heart Study cohort. 7 These subjects were 45 years old and free of cardiovascular disease at baseline, and were studied for a mean 32 years of follow-up. Both overweight (BMI 25-29.9 kg/m 2 ) and obesity (BMIX30 kg/m 2 ) were associated with a shorter life expectancy in men and women. A 45-yearold obese man with no CVD survived 6 years (95% confidence interval [CI]: 4.1; 8.1) fewer than his normalweight counterparts, whereas, for women, the difference between obese and normal-weight subjects was 8.4 years (95% CI: 6.2; 10.8). Lives of obese men and women spent with cardiovascular disease before death were 2.7 (95% CI: 1.0; 4.4) and 1.4 years (95% CI: À0.3; 3.2) more, respectively, than normal-weight individuals.
CVD risk calculation
Most premature cardiovascular disease in women is preventable. Evidence-based guidelines for the prevention of cardiovascular disease in women have been published. 8 These advocate that management should begin with a risk assessment.
Unlike earlier guidelines, the Third Joint European Society's Task Force on Cardiovascular Disease Prevention in Clinical Practice guidelines stress the need to prevent all Figure 1 Data from Sweden illustrate the decreases in myocardial infarction and death from ischaemic heart disease in men followed from the 1970s to the 1990s. However, in the same database, while similar trends were seen for women over the age of 65 years, as in men, these decreases were not seen in younger women. Reproduced with permission from Rosengren et al. ).
Obese women most at risk from cardiovascular disease S Tonstad atherosclerotic cardiovascular events rather than just coronary heart disease events. 9 Cardiovascular events other than coronary ones share the same risk factors with coronary events. Atherosclerotic cardiovascular disease is multifactorial in origin, and the causative risk factors interact to produce total risks that may be greater than the sum of the components. These guidelines, therefore, advocate using a total cardiovascular risk prediction system such as the Systematic Coronary Risk Evaluation (SCORE). This system is based on data from 12 European cohort studies and offers a simple way to estimate the risk of dying of cardiovascular disease over the next decade. 10 For women, however, the use of such risk-assessment tools poses several problems. SCORE, for instance, is based on fatal events, whereas it is known that the ratio of non-fatal to fatal events is higher in women than in men. Furthermore, the SCORE charts appear to indicate that women are at lower risk than men: the charts show that 60-year-old women have similar risk to 50-year-old men, giving women a 10-year advantage in risk. Women are not at lower risk than men in terms of their overall lifetime risk because their risk is delayed by 10-15 years. Data from the Framingham study suggest that a woman who is free of cardiovascular disease at age 50 years still has a lifetime risk for cardiovascular disease events of 39%. 11 It is suggested that risk is extrapolated to age 60 to determine what the risk will be if the present risk status continues until that age. The SCORE data give death rates of just 1-2% for the majority of women aged 55 years or below. This means that a woman below the age of 60 will need to have extremely high blood pressure or markedly elevated serum cholesterol levels and to be a smoker before she is likely to be at high enough risk to qualify for primary prevention drug treatment. An obese woman with mildly elevated risk factors would not be eligible for treatment. So while it is true that younger women are at low absolute risk, this may conceal very large RRs.
A further problem with using the SCORE risk calculator in estimating the risk of an obese woman is that the data that form the basis of SCORE were collected in the 1970s and 1980s, at least a decade before the current wave of obesity. Updated risk calculators based on data collected from populations examined in the 1990s are urgently needed.
Gender and cardiovascular disease risk factors
The identification of risk factors and their control through preventive measures has contributed to a reduction in cardiovascular and related mortality in both men and women.
Essentially, the same modifiable risk factors are known to increase risk in both men and women. These include type 2 diabetes, hypertension, smoking, abdominal obesity, poor exercise capacity, the so-called lipid triad of a lowered concentration of HDL-cholesterol and elevated concentrations of triglycerides and small dense low-density lipoprotein (LDL)-cholesterol (a central element of the metabolic syndrome) and elevated high-sensitivity C-reactive protein (CRP).
While the presence of any of these risk factors may increase risk in middle-aged women substantially, several of these factors appear to increase the risk of cardiovascular disease relatively more in women than in men in some or most studies.
Tobacco use
Tobacco use is an important risk factor among both men and women and in some studies may increase the RR associated with cardiovascular disease more in women than in men. 12 While the prevalence of smoking is still slightly higher in men than in women in Western Europe, the decline in tobacco use among women is less evident than in men. Cigarette smoking is thought to have anti-oestrogenic effects. In young women who smoke, the use of oral contraceptives further increases the risk. 13 Hypertension Although overall rates of hypertension are higher in men, elderly hypertensive women are an important at-risk group.
14 More women than men develop hypertension as they get older, particularly women over 45 years. 6 Lipid triad abnormalities Hypertriglyceridaemia and low HDL-cholesterol are more important risk factors in women than in men in some studies and relate to the metabolic syndrome, as described below.
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Type 2 diabetes
The prevalence of diabetes is increasing in both men and women. 16 While there has been controversy about the precise degree of excess risk attributable to type 2 diabetes in women, a recent meta-analysis of 37 studies of type 2 diabetes and fatal coronary heart disease involving a total of 447 064 patients showed a clear heterogeneity between men and women. 17 After exclusion of eight studies that had adjusted only for age, it was found that the presence of type 2 diabetes doubled the risk of fatal coronary heart disease in men, but quadrupled the risk in women. The pooled ratio of the RRs (women/men) from these 29 studies with multiple adjusted estimates was 1.46 (1.14-1.88). Thus, the RR for fatal coronary heart disease associated with diabetes is almost 50% higher in women than it is in men.
One reason that type 2 diabetes increases the risk of CVD in women to close to that of men is that type 2 diabetes is associated with changes in the lipid triad causing a woman's profile to be similar to that of a man.
Obese women most at risk from cardiovascular disease S Tonstad Certainly, there is evidence of gender-related changes in LDL-cholesterol density. Data from the Strong Heart Study indicate differences in LDL-cholesterol size in people with and without type 2 diabetes. 18 The study shows LDL-cholesterol size getting worse in a graded manner as women progress from normal glucose tolerance to impaired glucose tolerance to type 2 diabetes. While women have a clear advantage in their LDL-cholesterol size as long as they have normal glucose tolerance and even impaired glucose tolerance, once type 2 diabetes is present women resemble men in their LDL-cholesterol density and size ( Figure 3 ).
Metabolic syndrome
The risk of cardiovascular events is increased especially in women with central obesity, 19 because of the concomitance of other risk factors or co-morbidities, which are often present in obese women. In fact, the metabolic syndrome, defined by the presence of three or more risk factors, which include central obesity, is more prevalent in women than in men with coronary heart disease. 20 The metabolic syndrome has been shown to provide an additional boost to the cardiovascular risk of women compared to that of men. A meta-analysis of 21 prospective studies that examined the association between the metabolic syndrome and risk of cardiovascular disease found that individuals with the metabolic syndrome, compared to those without, had an increased incidence of mortality from all causes (RR 1.35; 95% CI, 1.17-1.56), mortality from cardiovascular disease (RR 1.74; 95% CI, 1.29-2.35) and cardiovascular disease (RR 1.53; 95% CI, 1.26-1.87). 21 However, the RR of cardiovascular disease associated with the metabolic syndrome was higher in women compared with men (RR 2.10; 95% CI, 1.79-2.45 versus RR 1.57; 95% CI, 1.41-1.75).
This strongly suggests that the detection, prevention and treatment of the underlying risk factors of the metabolic syndrome should become an important approach for the reduction of the cardiovascular disease burden in the general population but in women in particular.
Novel risk factors
Recent studies have focused on the effect of novel biomarkers including inflammatory markers on risk of cardiovascular disease. High-sensitivity CRP may play an important role in cardiovascular disease risk assessment in women.
There is a suggestion that women may have more favourable levels of some novel risk factors compared with men. One study compared markers of endothelial dysfunction, oxidation, thrombosis and inflammation, and adipokines in 207 men and high-risk premenopausal women aged 18-39 years with dyslipidaemia and a family history of premature coronary heart disease ( Table 2) . 22 The study found that women had more favourable or similar concentrations of 16 of the 17 novel risk factors studied compared with men. However, they tended to have higher levels of CRP. Measurement of CRP may improve CVD risk classification in women, particularly among those with a lowto-intermediate risk of CVD 23 and may better predict the risk of type 2 diabetes in women than in men. 24 Data from the cross-sectional Women's Health Study have clarified the relationship between risk factors, physical activity and BMI in 27 158 apparently healthy US women (mean age, 55 years). 25 Levels of cardiovascular and metabolic risk factors were more favourable in women who undertook more physical activity and in women with lower BMI. The influence of BMI on cardiovascular and metabolic risk factors was stronger than that of physical activity. Adjustment for physical activity exerted little effect on the relationships between BMI and levels of cardiovascular and metabolic parameters. Women with comparable obesity benefited from higher physical activity. The odds ratios for CRP 43 mg l À1 in active (41000 kcal of physical activity per week) and inactive overweight women (BMI 25-29.9 kg/m 2 ) were 2.7 and 3.1, respectively, with corresponding odds Figure 3 LDL-cholesterol size in subjects with and without type 2 diabetes in the Strong Heart Study (adapted from Gray et al.
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). Table 2 Markers of endothelial dysfunction, oxidation, thrombosis and inflammation, and adipokines in 207 men and high-risk premenopausal women aged 18-39 years with dyslipidaemia and a family history of premature coronary heart disease (Tonstad et al. 22 ) Obese women most at risk from cardiovascular disease S Tonstad ratios for active and inactive obese women (BMI430 kg/m 2 ) of 8.3 and 9.9, respectively (Po0.001 for each).
Low exercise capacity
Women experience a greater loss in their physical functioning with ageing when compared to their male counterparts. 14 
Risk estimation in clinical practice
It seems unlikely that general practitioners (GPs) are aware of which women are at increased risk of CVD. A study from Sweden asked 60 GPs to estimate the Framingham risk score of authentic written case descriptions of patients, all with a cholesterol value of at least 5.5 mmol l À1 and with variations in seven other variables. 26 The results were instructive. For a 51-year-old female smoker with a total cholesterol of 6.5 mmol dl À1 and an LDL-cholesterol of 4.1 mmol l À1 and an actual Framingham risk of 14%, the GPs estimated her risk at 5%. Essentially, the GPs appeared to ignore the impact of smoking on this middle-aged woman's risk. Similarly, for a 66-year-old diabetic woman with a total cholesterol of 6.9 mmol dl À1 and an LDL-cholesterol of 4.6 mmol l À1 and an actual Framingham risk score of 27%, the GPs estimated her risk at only 10%. Clearly, type 2 diabetes changes a woman's risk profoundly, but this excess risk was not perceived by her GP.
Clinical case history
Patient X was a 59-year-old school nurse who took part in a health screening programme, for which she presented to the preventive cardiology clinic. She was widowed, worked parttime and had 50% disability due to spinal stenosis. There was no family history of premature cardiovascular disease; however, her father had committed suicide at the age of 47, and so had not lived out the full potential of any risk. She had been treated for hypertension from the age of 45 years and was well-controlled with lisinopril 20 mg. She had a past history of depression, which was treated with citalopram, and she was not taking hormone replacement therapy. She did not smoke or drink alcohol, and because of a spinal stenosis she experienced back pain if she walked for more than about 100 m, for which she was taking paracetamol and other pain medications as needed.
Upon physical examination, her blood pressure was found to be 134/80 mm Hg, while she had normal heart and lung sounds and a normal electrocardiogram.
Laboratory results taken in the fasting condition revealed a total cholesterol of 6.6 mmol l
À1
, an HDL-cholesterol of This woman clearly has all five characteristics of the metabolic syndrome, which means that she has a high risk of developing type 2 diabetes within the next few years, and also a relatively high lifetime cardiovascular risk.
Several additional diagnostic tests would be advisable for such a patient. These would include a glucose tolerance test, urine testing for microalbuminuria and a high-sensitivity CRP test. Further optional tests might include ankle-brachial index and carotid intima-media thickness measurement. However, even without such tests, there is sufficient information to justify advising that the patient begin a programme of lifestyle change to achieve weight loss. Ideally this would encompass an increase in physical activity and a reduction in dietary intake, both supplemented by behavioural change and social support. However, given that this Maintenance (STORM) trial show that treatment with sibutramine and dietary intervention is associated with a clinically significant reduction in waist circumference compared to the dietary intervention alone, together with beneficial changes in triglycerides, VLDL-cholesterol and HDL-cholesterol (adapted from James et al. 27 ) y Placebo patients received sibutramine during the first 6 months.
patient is unlikely to take physical activityFshe develops pain upon walkingFand may well have an unrestrained approach to eating, with a fondness for cakes and highenergy foods, there may be a strong case for treatment with weight-loss drugs in addition.
Data from the Sibutramine Trial of Obesity Reduction and Maintenance (STORM), which included primarily middleaged women, show that after 1 year's treatment with sibutramine and dietary intervention, there was a clinically significant reduction in waist circumference compared to the dietary intervention alone. 27 Furthermore, there were also advantageous changes in triglycerides, very low-density lipoprotein (VLDL)-cholesterol and HDL-cholesterol (Figure 4) . Analyses by the Cochrane Collaboration indicate that weight reduction of a similar magnitude would be achieved with orlistat and rimonabant, and that treatment with rimonabant would result in similar improvements in lipid parameters to sibutramine, while treatment with orlistat would show a selective lowering of LDL-cholesterol concentrations.
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Summary
Obesity is an important cause of cardiovascular disease in women that is not taken into account in risk-assessment calculators used in everyday clinical practice.
Type 2 diabetes causes a woman's absolute risk to approach that of men with diabetes. Some established and novel cardiovascular risk factors appear to increase cardiovascular risk relatively more in middle-aged women than in men.
There is a need to take a multifactorial approach to prevention focusing on multiple risk reduction. Weight loss is a crucial therapeutic goal as this may decrease the risk of type 2 diabetes and reduce the risk of cardiovascular morbidity and mortality. Lifestyle changes and pharmaceutical interventions that have been shown to improve cardiovascular risk factors should be considered in overweight and obese patients.
